Stock Price Forecast

Dec. 8, 2022


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Adicet Bio Inc chart...

About the Company

Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of 'off-the-shelf' gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients.

CEO

Chen Schor

Exchange

NASDAQ

Website

www.adicetbio.com

$39M

Total Revenue

82

Employees

$851M

Market Capitalization

-11.13

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ACET News

What Makes Adicet Bio, Inc. (ACET) a Good Fit for 'Trend Investing'

1d ago, source:

This predefined screen makes it really easy to shortlist the stocks that have enough fundamental strength to maintain their recent uptrend. Also, the screen passes only the stocks that are trading in ...

Is Adicet Bio (ACET) Stock Outpacing Its Medical Peers This Year?

1d ago, source:

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Adicet Bio, Inc. (ACET) is a stock that can certainly grab the attention of many ...

Adicet Bio Appoints Nancy Boman, M.D., Ph.D., as Senior Vice President and Chief Regulatory Officer

9d ago, source: Yahoo

REDWOOD CITY, Calif. & BOSTON, November 29, 2022--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell ...

Wall Street Analysts Think Adicet Bio, Inc. (ACET) Could Surge 72%: Read This Before Placing a Bet

9d ago, source: Nasdaq

Shares of Adicet Bio, Inc. (ACET) have gained 1.3% over the past four weeks to close the last trading session at $16.70, but there could still be a solid upside left in the stock if short-term ...

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

8d ago, source: Yahoo

REDWOOD CITY, Calif. & BOSTON, December 01, 2022--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell ...

Adicet Bio to Present at the Virtual JMP Securities Hematology and Oncology Summit

8d ago, source:

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T ...

Adicet Bio Appoints Nancy Boman, M.D., Ph.D., as Senior Vice President and Chief Regulatory Officer

9d ago, source: Morningstar%2c Inc.

Get 7 Days Free Sign In Sign In Topics ...

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

8d ago, source: Benzinga.com

Adicet Bio, Inc. ACET, a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...